文献速递前列腺癌

大型全国队列中保留阿片类药物的根治性前列腺切除术的预测因素与趋势

Predictors and Trends of Opioid-Sparing Radical Prostatectomy From a Large National Cohort.
PubMed 文献 · Urology · 2022-08-02

基于Premier医院数据库2015年1月至2020年3月62,660例机器人及腹腔镜根治性前列腺切除术患者,23.6%为保留阿片类药物。多因素回归显示酮咯酸是最强预测因素(OR 1.86,95%CI 1.79-1.93),黑人种族预测非保留阿片类药物(OR 0.75,95%CI 0.71-0.80)。酮咯酸未增加术后出血或透析风险。

要点

  • 保留阿片类药物前列腺切除术占23.6%,与高龄、白人种族、高手术量医生及多种非阿片类药物相关。
  • 静脉酮咯酸是最强预测因素(OR 1.86,95%CI 1.79-1.93),黑人种族预测非保留(OR 0.75,95%CI 0.71-0.80)。
  • 酮咯酸未增加术后出血(0.3% vs 0.3%,P=1.0)或透析需求(<0.1% vs <0.1%,P=.91)。

核心结论

  • 保留阿片类药物的根治性前列腺切除术可行,且与所用每种非阿片类镇痛药的使用相关。
  • 酮咯酸是最强预测因素,且未增加出血或透析风险。

研究设计与样本

  • 查询Premier医院数据库,纳入2015年1月至2020年3月所有住院时间≥1天的机器人和腹腔镜根治性前列腺切除术。
  • 共纳入62,660例患者,比较保留阿片类药物与非保留阿片类药物前列腺切除术,采用逻辑多因素回归识别预测因素。

主要发现

  • 14,806例(23.6%)行保留阿片类药物前列腺切除术。
  • 保留阿片类药物组与较老年龄(65 vs 63岁,P<.01)、白人 vs 黑人种族(76.3% vs 73.4%,P<.01)、高手术量医生(75.2% vs 70.0%,P<.01)、静脉酮咯酸(62.2% vs 48.0%,P<.01)、静脉对乙酰氨基酚(32.5% vs 30.1%,P<.01)及脂质体布比卡因(5.4% vs 4.9%,P<.01)相关。
  • 多因素回归中酮咯酸是最强预测因素(OR 1.86,95%CI 1.79-1.93,P<.01),黑人种族预测非保留阿片类药物(OR 0.75,95%CI 0.71-0.80,P<.01)。
  • 酮咯酸与术后出血风险增加无关(0.3% vs 0.3%,P=1.0),与透析需求增加无关(<0.1% vs <0.1%,P=.91)。

关键数值与推荐

  • 保留阿片类药物定义为术后第0天之后无静脉阿片类药物使用且整个住院期间无口服阿片类药物使用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the use of pain medications after radical prostatectomy using a large national database. METHODS: The Premier Hospital Database was queried to identify all robotic and laparoscopic radical prostatectomies from January 2015 to March 2020 with length of stay more than or equal to 1 day. "Opioid-sparing" was defined as absence of intravenous opioid use after post-operative day 0 and absence of oral opioid use throughout admission. Comparisons were made between opioid-sparing and non-opioid-sparing prostatectomy. Logistic multivariable regression was used to identify predictors of opioid-sparing prostatectomy. RESULTS: A total of 62,660 patients were included, of whom 14,806 (23.6%) underwent opioid-sparing prostatectomy. Opioid-sparing prostatectomy was associated with older age (65 vs 63 years, P <.01), white versus black race (76.3% vs 73.4%, P <.01), high-volume surgeons (75.2% vs 70.0%, P <.01), and use of intravenous ketorolac (62.2% vs 48.0%, P <.01), intravenous acetaminophen (32.5% vs 30.1%, P <.01), and liposomal bupivacaine (5.4% vs 4.9%, P <.01). On multivariable regression, ketorolac was the strongest predictor of opioid-sparing prostatectomy (odds ratio: 1.86, 95% confidence interval: 1.79-1.93, P <.01), and black race was predictive of non-opioid sparing prostatectomy (odds ratio: 0.75, 95% confidence interval: 0.71-0.80, P <.01). Ketorolac was not associated with increased risk of postoperative bleeding (0.3% vs 0.3%, P =1.0) or dialysis requirement (<0.1% vs <0.1%, P =.91). CONCLUSION: Opioid-sparing radical prostatectomy was feasible and associated with administration of each of the non-opioid pain medications assessed. Ketorolac was the strongest predictor of opioid-sparing prostatectomy and was not associated with increased risk of bleeding or dialysis.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Brant A, Lewicki P, Johnson JP, et al. Predictors and Trends of Opioid-Sparing Radical Prostatectomy From a Large National Cohort. Urology. 2022. PMID: 35931239. doi:10.1016/j.urology.2022.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。